NeoGenomics Q4 revenue +11% to $172M; FY24 $661M; guides FY25 rev $735-745M

NEOGENOMICS INC

Q4 consolidated revenue $172M (up 11% YoY); net loss $15M vs $14M in Q4 2023.
FY24 consolidated revenue $661M (+12% YoY); net loss $79M (improved from $88M).
Adjusted EBITDA FY24 positive $40M vs $3M in 2023, a 1,036% increase.
FY2025 guidance: revenue $735-745M (11-13% growth); adjusted EBITDA $55-58M.
Ninth consecutive quarter of double-digit revenue growth; NGS grew 34% in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.